RT Journal Article
SR Electronic
T1 Whole-Genome Sequencing Of Omicron Identified Multiple Outbreaks And Introduction Events In India During November 2021 and January 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.20.22270880
DO 10.1101/2022.04.20.22270880
A1 Marathe, Shreedhanya D
A1 Shamanna, Varun
A1 Nagaraj, Geetha
A1 Nischita, S
A1 Bhaskaran, Muthumeenakshi
A1 Ravikumar, K L
YR 2022
UL http://medrxiv.org/content/early/2022/04/25/2022.04.20.22270880.abstract
AB The variant of Concern(VOC), Omicron is the predominant variant circulating throughout the world of the SARS COV2 pandemic during the third wave including India. The World Health Organisation has designated this highly mutated variant as a VOC due to its high transmissibility and risk of reinfection. Whole-genome sequencing and analysis were performed for SARS-CoV2 PCR positive samples between Dec21 to Jan22. From the 133 omicron variants detected, genomic analysis was carried out by contextualizing them with 1586 complete genomes of Omicron from India obtained from GISAID.The Omicron variant prevalence in India has increased in a log phase within 3 months in most of the metropolitan cities. The sublineage BA.1 was first observed in the country, while the BA.2 sublineage was introduced to Delhi in the mid of December 2021. The two outbreaks observed were of BA.2 variant and were observed to spread to multiple cities in a short time. The rapid spread and specific mutations in the outbreak samples of Omicron indicate that the variant is highly transmissible when compared to previous variants. The study shows the importance of genomic sequence to identify the emergence of clusters and take actions to prevent further spreading events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare no funding was received for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kempegowda Institute of Medical Science independent ethics committee (Approval ID: KIMS/IEC/A012/M/2022). The study was conducted according to the guidelines and recommendations of Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from each participant or legal guardian as applicable. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll supporting data, code and protocols have been provided within the article or through supplementary data files. https://microreact.org/project/6hU3Rp3Wf8yDK24E2mBvh5-omicronindiafirst https://microreact.org/project/2H1zuFXnnAuwvhREBJrW7L-omicronfirstoutbreak https://microreact.org/project/ankEHTJjr93qMegr4AfJTD-omicronindia